Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

CONCLUSIONS: MAGNITUDE, enrolling the largest BRCA1/2 cohort in first-line mCRPC to date, demonstrated improved rPFS and other clinically relevant outcomes with niraparib plus AAP in patients with BRCA1/2-altered mCRPC, emphasizing the importance of identifying this molecular subset of patients.PMID:37399894 | DOI:10.1016/j.annonc.2023.06.009

Source: Ann Oncol - July 3, 2023 Category: Cancer & Oncology Authors: K N Chi S Sandhu M R Smith G Attard M Saad D Olmos E Castro G Roubaud A J Pereira de Santana Gomes E J Small D E Rathkopf H Gurney W Jung G E Mason S Dibaj D Wu B Diorio K Urtishak A Del Corral P Francis W Kim E Efstathiou Source Type: research